Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Anika Therapeutics (ANIK)

Anika Therapeutics (ANIK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 326,748
  • Shares Outstanding, K 14,600
  • Annual Sales, $ 147,790 K
  • Annual Income, $ 4,130 K
  • 60-Month Beta 1.00
  • Price/Sales 2.15
  • Price/Cash Flow 15.38
  • Price/Book 1.11
Trade ANIK with:

Options Overview Details

View History
  • Implied Volatility 84.29% ( +3.72%)
  • Historical Volatility 40.82%
  • IV Percentile 77%
  • IV Rank 60.97%
  • IV High 118.75% on 04/21/22
  • IV Low 30.48% on 11/16/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 132
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 923
  • Open Int (30-Day) 590

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year 0.05
  • Growth Rate Est. (year over year) -460.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.60 +3.61%
on 08/12/22
25.20 -11.21%
on 08/03/22
-0.23 (-1.02%)
since 07/12/22
3-Month
20.12 +11.23%
on 06/13/22
25.20 -11.21%
on 08/03/22
+0.54 (+2.47%)
since 05/12/22
52-Week
19.95 +12.18%
on 05/06/22
45.81 -51.15%
on 11/05/21
-18.31 (-45.00%)
since 08/12/21

Most Recent Stories

More News
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

Anika (ANIK) delivered earnings and revenue surprises of 23.08% and 8.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ANIK : 22.38 (+2.94%)
BNGO : 3.60 (+6.51%)
Anika Reports Second Quarter Fiscal 2022 Financial Results

Second quarter revenue growth up 4%X-Twist™ 510(k) clearance received; Limited market release on schedule for 2H 2022 BEDFORD, Mass., Aug. 03, 2022 ...

ANIK : 22.38 (+2.94%)
Anika Receives the ACE Award for Cutting-Edge Innovation for Tactoset® Injectable Bone Substitute from the American Orthopedic Society for Sports Medicine

BEDFORD, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on...

ANIK : 22.38 (+2.94%)
Apellis' (APLS) Geographic Atrophy NDA Gets Priority Review

The FDA accepts Apellis' (APLS) NDA for pegcetacoplan under a priority review for treating geographic atrophy secondary to age-related macular degeneration. A decision is due on Nov 26, 2022.

CLDX : 37.33 (+8.11%)
BEAM : 69.08 (+4.52%)
ANIK : 22.38 (+2.94%)
APLS : 67.95 (+3.80%)
Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate

Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.

BEAM : 69.08 (+4.52%)
ANIK : 22.38 (+2.94%)
FATE : 33.82 (+3.58%)
ACAD : 16.40 (+4.19%)
Ultragenyx (RARE) Provides Update From Angelman Syndrome Study

Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.

BEAM : 69.08 (+4.52%)
ANIK : 22.38 (+2.94%)
RARE : 51.57 (+0.62%)
FATE : 33.82 (+3.58%)
Anika to Issue Second Quarter 2022 Financial Results on Wednesday, August 3, 2022

BEDFORD, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention...

ANIK : 22.38 (+2.94%)
Sidoti's Summer Small Cap Virtual Conference

NEW YORK, NY / ACCESSWIRE / June 14, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day Summer Small Cap Virtual Conference taking place Wednesday and Thursday,...

AZZ : 46.64 (+1.81%)
GAIA : 3.24 (-0.61%)
MDV : 15.95 (-0.62%)
SGC : 14.21 (-0.70%)
ERII : 23.94 (+5.00%)
MG : 6.63 (+0.91%)
LXU : 13.63 (+3.34%)
DFIN : 44.25 (+3.24%)
GRID.TO : 1.31 (-0.76%)
HSII : 31.47 (-0.41%)
CASY : 208.43 (+0.98%)
ANIK : 22.38 (+2.94%)
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference

BEDFORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention...

ANIK : 22.38 (+2.94%)
Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio

X-Twist provides a simple, versatile knotless suture anchor system ideal for key repairs in the shoulder, foot and ankle, and other extremities...

ANIK : 22.38 (+2.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative...

See More

Key Turning Points

3rd Resistance Point 23.59
2nd Resistance Point 23.04
1st Resistance Point 22.71
Last Price 22.38
1st Support Level 21.82
2nd Support Level 21.27
3rd Support Level 20.94

See More

52-Week High 45.81
Fibonacci 61.8% 35.93
Fibonacci 50% 32.88
Fibonacci 38.2% 29.83
Last Price 22.38
52-Week Low 19.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar